Factors which can make patients difficult to treat

British Journal of Psychiatry

Volumn 169, Issue DEC. SUPPL. 31, 1996, Pages 10-14

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

HUMAN; PATIENT COMPLIANCE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; THERAPY RESISTANCE; CLASSIFICATION; CLINICAL TRIAL; COMORBIDITY; DRUG RESISTANCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; ADVERSE EVENT; ARTICLE; PROBLEM PATIENT; PSYCHIATRIC TREATMENT;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; COMORBIDITY; DRUG RESISTANCE; HUMANS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0029906650     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/s0007125000298565     Document Type: Review

References (28)

1. BREIER, A., BUCHANAN, R. W., KIRKPATRICK, B., et al (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry, 151, 20 26.
2. COLE, J. O., GOLDBERG, S. C. & DAVIS, J. M. (1966) Drugs in the treatment of psychosis: controlled studies. In Psychiatric Drugs (ed. P. Solomon), pp. 153 180. New York: Groller and Stratton.
3. DRAKE, R. E., MCLAUGHLIN, P., PEPPER, B., et al (1991) Dual diagnosis of major mental illness and substance abuse disorder: an overview. New Directions in Mental Health Services, 50, 3 12.
4. ESSOCK, S. M., HARGREAVES, W. A., DOHM, F. A., et al (1996) Clozapine eligibility among state hospital patients. Schizophrenia Bulletin, 22, 15-25.
5. GALANTER, M., CASTENADA, R. & FERMAN, J. (1988) Substance abuse among general psychiatric patients: place of presentation. diagnosis and treatment. American Journal of Drug and Alcohol Abuse, 142, 211-235.
6. HONIGFELD, G., GILLIS, R. D. & KLETT, C. J. (1966) NOSIE-30: a treatment-sensitive ward behaviour scale. Psychological Reports, 19, 180 182.
7. JESTE, D. V. & CALIGIURI, M. P. (1993) Tardive dyskinesia. Schizophrenia Bulletin, 19, 303-316.
8. JUAREZ-REYES, M. G., SHUMWAY, M., BATTLE, C., et al (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 76, 801-806.
9. KANE, J. M. (1985) Compliance issues in outpatient treatment. Journal of Clinical Psychopharmacology, 5, 22S-27S.
10. _ (1995) Tardive dykinesia. Presented at the International Congress on Schizophrenia Research Meeting. Warm Springs. Virginia, April 12, 1995.
11. , HONIGFELD, G., SINGER, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Archives of General Psychiatry, 45, 789-796.
12. _, SAFFERMAN, A. Z., POLLACK, S., et al (1994) Clozapine, negative symptoms and extrapyramidal side effects. Journal of Clinical Psychiatry, 55 (Suppl. B), 74-78.
13. _, MARDER, S. R., SCHOOLER, N., et al (1995) Efficacy of clozapine vs. haloperidol in a long-term clinical trial. Presented at the American Psychiatric Association Meeting. Miami, Florida, May 24, 1995.
14. KINON, B. J., KANE, J. M., JOHNS, C., et al (1993) Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacology Bulletin, 29, 309 314.
15. LEVINSON, D. F., SIMPSON, G. M., SINGH, H., et al (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry, 47, 761 768.
16. LIEBERMAN, J. A., JODY, D., ALVIR, J. M. J., et al (1991) Negative symptoms in schizophrenia: relationship to positive symptoms and outcome. In Negative versus Positive Schizophrenia (eds A. Marneras, N. C. Andreasen & M. T. Tsuang), pp. 109 125. Berlin: Springer-Verlag.
17. MARDER, S. R. & MEIBACH, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
18. MCEVOY, J. P., HOGARTY, G. & STEINGARD, S. (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry, 48, 739 745.
19. OVERALL, J. E. & GORHAM, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
20. REGIER, D. A., FARMER, M. E., RAE, D. S., et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264, 2511 2518.
21. REMINGTON, G., POLLOCK, B., VOINESKOS, G., et al (1993) Acutely psychotic patients receiving high-dose haloperidol therapy. Journal of Clinical Psychopharmacology, 13, 41-45.
22. RIFKIN, A., DODDI, S., KARAGI, B., et al (1991) Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166 170.
23. SAFFERMAN, A. Z., KANE, J. M., ARONOWITZ, J. S., et al (1994) The use of clozapine in neurologic disorders. Journal of Clinical Psychiatry, 5 (Suppl. B), 98-101.
24. SHANER, A., KHALSA, M. E., ROBERTS, L. J., et al (1993) Unrecognized cocaine use among schizophrenic patients. American Journal of Psychiatry, 150, 758-762.
25. SIRIS, S. G., MORGAN, V., FAGERSTROM, R., et al (1987) Adjunctive imipramine in the treatment of post psychotic depression: a controlled trial. Archives of General Psychiatry, 44, 533 539.
26. TERKELSEN, K. G. & GROSSER, R. C. (1990) Estimating clozapine's cost to the nation. Hospital and Community Psychiatry, 41, 863-869.
27. VAN PUTTEN, T., MARDER, S. R. & MINTZ, J. A. (1990) Controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754 758.
28. YESAVAGE, J. & ZARCONE, V. (1993) History of drug abuse and dangerous behaviour in inpatient schizophrenics. Journal of Clinical Psychiatry, 44, 259 261.